Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The move is expected to be crucial during health crises
Subscribe To Our Newsletter & Stay Updated